In preclinical and clinical models, agents that target the VEGF signaling pathway have the potential to normalize tumor vasculature, decrease permeability, alleviate edema, lower IFP, improve tissue oxygen levels, and enhance the efficacy of cytotoxic therapies like radiation, chemotherapy, or immunotherapy (32–34). This evidence concerns the gene VEGFA and neoplasm.